In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: results from OPAL-HK

Session Poster session 1 Saturday 08:30 -17:30

Speaker Bertram Pitt

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P397

Authors : B Pitt (Ann Arbor,US), MR Weir (Baltimore,US), MR Mayo (Redwood City,US), D Garza (Redwood City,US), H Christ-Schmidt (Washington, DC,US), J Wittes (Washington, DC,US), L Berman (Redwood City,US)

Authors:
B Pitt1 , MR Weir2 , MR Mayo3 , D Garza3 , H Christ-Schmidt4 , J Wittes4 , L Berman3 , 1University of Michigan School of Medicine - Ann Arbor - United States of America , 2University of Maryland School of Medicine - Baltimore - United States of America , 3Relypsa, Inc. - Redwood City - United States of America , 4Statistics Collaborative, Inc. - Washington, DC - United States of America ,

On behalf: OPAL-HK Investigators

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 90

Purpose: Patients (pts) with heart failure (HF) and chronic kidney disease (CKD) are at risk for hyperkalemia (HK), especially when treated with renin angiotensin aldosterone system inhibitors (RAASi). Patiromer, the active moiety of which is a nonabsorbed potassium (K+)-binder, was previously shown in clinical trials to lower serum K+ (s-K+) with good gastrointestinal tolerability. This was a two-phase multicenter international study in 243 pts with HK and an eGFR 15-<60 mL/min/1.73m2 with/without HF on RAASi. This prespecified subgroup analysis presents the findings in CKD pts with (n = 102) and without HF (n = 141).

Methods: Phase 1, a 4-wk single-blind treatment study, assessed patiromer for HK treatment. Phase 2, an 8-week placebo-controlled randomized withdrawal study, assessed whether chronic patiromer treatment prevented recurrent HK. Primary outcomes were change from baseline in s-K+ (Phase 1) and the between group difference in change in s-K+ from Phase 2 Baseline to Phase 2 Wk 4 (Phase 2). Secondary outcomes included the proportion with s-K+ in the target range (Phase 1) and the proportion with recurrent HK (Phase 2).

Results: The mean (±SE) change in s-K+ from baseline to week 4 was −1.06 ± 0.05 mEq/L (95% CI, −1.16 to −0.95, p < 0.001) in pts with HF and −0.98 ± 0.04 (95% CI, −1.06 to −0.90, p < 0.001) in pts without HF (p value for interaction, 0.22). Serum K+ was controlled (3.8-<5.1 mEq/L) at the end of Phase 1 in 76% of HF and 75% of non-HF pts. Primary endpoint results for Phase 2 are shown in the Table. Significantly (p < 0.001) more placebo than patiromer pts (HF, 52% vs 8%; non-HF, 66% vs 23%) developed recurrent HK (s-K+ >5.5 mEq/L) during Phase 2. Patiromer was well tolerated; constipation (none severe) was the most common adverse event with patiromer in both pts with/without HF (11% and 4% in Parts 1 and 2, respectively).

Conclusions: Patiromer provided effective s-K+ control and, compared to placebo, decreased HK recurrence in CKD pts with and without HF, with a well-tolerated safety profile that may allow continuous management of s-K+ in HF pts with HK on RAASi.

Median Change in Serum K+ from Phase 2 Baseline to Phase 2 Week 4

Between-Group Difference in Medians, 95% CI (p-value)

Interaction p-value

Placebo

Patiromer

Heart Failure Present

(n = 49, 46%)

0.74 mEq/L

0.10 mEq/L

0.64 mEq/L, 95% CI: 0.29, 0.99

(p < 0.001)

0.50

Heart Failure

Absent

(n = 58, 54%)

0.78 mEq/L

-0.05 mEq/L

0.83 mEq/L, 95% CI: 0.42, 1.24

(p < 0.001)

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are